利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.03 秒)

    Anti-CD3epsilon antibodies
    5.
    发明授权
    Anti-CD3epsilon antibodies 有权

    公开(公告)号：US11440962B2

    公开(公告)日：2022-09-13

    申请号：US16649149

    申请日：2018-09-20

    申请人： WuXi Biologics Ireland Limited

    发明人： Jing Li ,  Qin Mei

    IPC分类号： C07K16/28 ,  A61K47/68

    摘要： The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

    Anti-PD-1 antibodies
    6.
    发明授权
    Anti-PD-1 antibodies 有权

    公开(公告)号：US11008391B2

    公开(公告)日：2021-05-18

    申请号：US15751236

    申请日：2016-08-11

    申请人： WuXi Biologics Ireland Limited

    发明人： Yong Zheng ,  Jing Li ,  Zhisheng Chen

    IPC分类号： C07K16/28

    摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

    Bispecific CD3/CD19 polypeptide complexes
    9.
    发明授权
    Bispecific CD3/CD19 polypeptide complexes 有权

    公开(公告)号：US11365254B2

    公开(公告)日：2022-06-21

    申请号：US16648792

    申请日：2018-09-20

    申请人： WUXI BIOLOGICS IRELAND LIMITED

    发明人： Jieying Liu ,  Jianqing Xu ,  Zhuozhi Wang ,  Qin Mei ,  Jing Li

    IPC分类号： C07K16/28 ,  C12N15/63 ,  A61P35/00 ,  G01N33/68 ,  A61K39/00

    摘要： A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.